MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-16-2026
Isoray Income Statement 2011-2026 | ISR
Annual Income Statement Isoray
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
- | 24.5 M | 10.2 M | 42.6 M | 53.9 M | 115 M | 25.5 M | 36.4 M | 33.6 M | 42.4 M | 75.7 M | 109 M | 21 M | 31.2 M | 25.9 M |
Shares |
73.8 M | 64.4 M | 26.8 M | 142 M | 142 M | 67.6 M | 67 M | 55.2 M | 55 M | 55 M | 54.9 M | 42.7 M | 34.4 M | 28.6 M | 25.1 M |
Historical Prices |
- | 0.38 | 0.38 | 0.3 | 0.38 | 1.7 | 0.8 | 0.45 | 0.48 | 0.6 | 0.72 | 1.34 | 0.74 | 0.71 | 0.63 |
Net Income |
-103 M | -79.3 M | -46.5 M | -7.34 M | -3.85 M | -3.45 M | -5.14 M | -6.7 M | -6.16 M | -4.71 M | -3.68 M | -5.96 M | -3.86 M | -3.49 M | -2.84 M |
Revenue |
- | - | - | 3.55 M | 5.38 M | 9.68 M | 7.31 M | 5.92 M | 4.76 M | 4.77 M | 4.61 M | 4.22 M | 4.53 M | 5.07 M | 5.24 M |
Cost of Revenue |
- | - | - | - | 3.13 M | 4.56 M | 4.27 M | 4.08 M | 3.92 M | 4.64 M | - | - | - | - | - |
Gross Profit |
- | - | - | 817 K | 2.25 M | 5.12 M | 3.05 M | 1.84 M | 838 K | 129 K | 167 K | -196 K | 150 K | 703 K | 1.16 M |
Operating Income |
-114 M | -90.9 M | -40.9 M | -5.62 M | -3.91 M | -3.48 M | -5.25 M | -6.73 M | -6.31 M | -5.08 M | -4.34 M | -4.59 M | -4.07 M | -3.6 M | -2.96 M |
Interest Expense |
- | - | - | - | - | - | 2 K | - | - | 950 | 2.21 K | 883 | 7 | - | - |
EBITDA |
-110 M | -88.6 M | -40 M | -5.48 M | -3.79 M | -3.33 M | -5.09 M | -6.6 M | -6.19 M | -4.5 M | -3.72 M | -3.87 M | -3.33 M | -2.75 M | -2.07 M |
Operating Expenses |
114 M | 92.3 M | 42.4 M | 5.62 M | 6.16 M | 8.6 M | 8.32 M | 8.57 M | 7.14 M | 5.21 M | 4.5 M | 4.39 M | 4.22 M | 4.3 M | 4.12 M |
General and Administrative Expenses |
30.2 M | 26.6 M | 21.1 M | 4.85 M | 3.46 M | 4.57 M | 4.17 M | 4.16 M | 3.92 M | 3.79 M | 2.4 M | 2.49 M | 2.29 M | 2.36 M | 2.42 M |
All numbers in USD currency
Quarterly Income Statement Isoray
| 2025-Q3 | 2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
74.3 M | 74.2 M | 70.7 M | 70.6 M | 66.6 M | 495 M | 28.2 M | 28.1 M | 28 M | 229 M | 142 M | 142 M | 142 M | 142 M | 142 M | 142 M | 142 M | 123 M | 83 M | 68.9 M | 83 M | 68.9 M | 67.4 M | 67.4 M | 67.4 M | 67.4 M | 67.3 M | 66.1 M | 67.3 M | 66.1 K | 55.1 M | 55 M | 55.1 M | 55 M | 55 M | 55 M | 55 M | 55 M | 55 M | 55 M | 55 M | 55 M | 54.9 M | 54.9 M | 54.9 M | 54.9 M | 38.4 M | 35.9 M | 38.4 M | 35.9 M | 34.6 M | 33.9 M | 34.6 M | 33.9 M | 28.6 M | 26.5 M | 26.4 M | 26.4 M |
Net Income |
-26 M | -21.5 M | - | -15.1 M | -11.7 M | -12.3 M | - | -10.4 M | -11.1 M | -371 K | - | -4.07 M | -2.08 M | -1.35 M | -1.6 M | -2.24 M | -1.6 M | -2.24 M | -868 K | -868 K | -868 K | -713 K | -897 K | -897 K | -897 K | -816 K | -1.41 M | -1.41 M | -1.41 M | -1.51 M | -1.46 M | -1.55 M | -1.46 M | -1.55 M | -1.45 M | -1.5 M | -1.45 M | -1.5 M | -1.31 M | -1.02 M | -1.31 M | -1.02 M | -907 K | -786 K | -907 K | -786 K | -927 K | -1.27 M | -927 K | -1.27 M | -1.15 M | -994 K | -1.15 M | -994 K | -629 K | -1.1 M | -629 K | -1.1 M |
Revenue |
- | - | - | - | - | - | - | 2.18 M | 2.09 M | 2.06 M | - | 1.72 M | 2.5 M | 2.91 M | 2.82 M | 2.56 M | 2.71 M | 2.6 M | 2.36 M | 2.38 M | 2.28 M | 2.88 M | 2.21 M | 2.32 M | 1.92 M | 1.92 M | 1.9 M | 1.56 M | 1.9 M | 1.56 M | 1.54 M | 1.21 M | 1.37 M | 1.28 M | 1.03 M | 1.08 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
- | - | - | - | - | - | - | 1.45 M | 1.84 M | 1.58 M | - | 1.3 M | 1.58 M | 1.47 M | 1.6 M | 1.54 M | 3.13 M | 1.24 M | 1.19 M | 1.14 M | 1.19 M | 1.14 M | 1.1 M | 1.08 M | 1.1 M | 1.08 M | 1.14 M | 1.04 M | 1.14 M | 1.04 M | 1 M | 946 K | - | 989 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | - | - | - | - | 738 K | 248 K | 487 K | - | 414 K | 926 K | 1.44 M | 1.22 M | 1.03 M | 2.25 M | 1.36 M | 1.17 M | 1.25 M | 1.17 M | 1.25 M | 1.11 M | 1.24 M | 1.11 M | 1.24 M | 765 K | 524 K | 765 K | 524 K | 531 K | 265 K | 531 K | 265 K | -1 K | 48 K | -1 K | 48 K | 30 K | 83 K | 26.9 K | 83.5 K | -38 K | -54.8 K | -38 K | -54.8 K | -33.9 K | -77.3 K | -33.9 K | -77.3 K | -159 K | -20.4 K | -159 K | -20.4 K | 199 K | 66.3 K | 199 K | 66.3 K |
Operating Income |
-27.9 M | -24 M | - | -18.6 M | -14.3 M | -13 M | - | -9.75 M | -9.75 M | -9.76 M | - | -4.21 M | -2.11 M | -1.38 M | -1.64 M | -2.27 M | -3.91 M | -766 K | -873 K | -714 K | -873 K | -714 K | -903 K | -836 K | -903 K | -836 K | -1.43 M | -1.52 M | -1.43 M | -1.52 M | -1.47 M | -1.55 M | -1.47 M | -1.55 M | -1.48 M | -1.58 M | -1.48 M | -1.58 M | -1.41 M | -1.09 M | -1.41 M | -1.09 M | -1.02 M | -1.16 M | -1.02 M | -1.16 M | -1.04 M | -1.23 M | -1.04 M | -1.23 M | -1.1 M | -1.12 M | -1.1 M | -1.12 M | -792 K | -1.1 M | -792 K | -1.1 M |
Interest Expense |
- | - | - | - | - | - | - | 14 K | 28 K | 18 K | - | - | - | - | - | - | - | - | - | - | - | - | - | 2 K | - | 2 K | - | - | - | - | - | - | - | - | - | - | - | - | - | 950 | 950 | 100 | - | 3.45 K | 3.45 K | 3.45 K | 86 | 741 | - | - | - | - | - | - | - | - | - | - |
EBITDA |
- | - | - | - | - | -12.7 M | - | -9.49 M | -9.5 M | -9.58 M | - | -4.14 M | -2.03 M | -1.3 M | -1.64 M | -2.22 M | -3.79 M | -766 K | -873 K | -680 K | -802 K | -680 K | -903 K | -798 K | -826 K | -798 K | -1.43 M | -1.49 M | -1.36 M | -1.49 M | -1.47 M | -1.53 M | -1.43 M | -1.53 M | -1.48 M | -1.56 M | -1.45 M | -1.58 M | -1.27 M | -954 K | -1.14 M | -954 K | -885 K | -991 K | -715 K | -991 K | -1.04 M | -1.06 M | -695 K | -1.06 M | -1.1 M | -916 K | -711 K | -916 K | -792 K | -886 K | -357 K | -886 K |
Operating Expenses |
28.1 M | 24.3 M | - | 19 M | 14.8 M | 13.3 M | - | 10 M | 10.3 M | 9.99 M | - | 4.62 M | 3.03 M | 2.82 M | 2.86 M | 3.3 M | 6.16 M | 2.13 M | 2.04 M | 1.96 M | 2.04 M | 1.96 M | 2.01 M | 2.07 M | 2.01 M | 2.07 M | 2.19 M | 2.04 M | 2.19 M | 2.04 M | 2 M | 1.82 M | 2 M | 1.82 M | 1.48 M | 1.62 M | 1.48 M | 1.62 M | 1.44 M | 1.17 M | 1.44 M | 1.17 M | 982 K | 1.11 M | 982 K | 1.11 M | 1.01 M | 1.16 M | 1.01 M | 1.16 M | 941 K | 1.1 M | 941 K | 1.1 M | 991 K | 1.17 M | 991 K | 1.17 M |
General and Administrative Expenses |
7.73 M | 7.71 M | - | 6.98 M | 5.51 M | 5.88 M | - | 4.47 M | 4.99 M | 6.66 M | - | 3.11 M | 1.58 M | 1.58 M | 1.62 M | 1.84 M | 3.46 M | 1.18 M | 1.13 M | 1.07 M | 1.13 M | 1.07 M | 1.07 M | 1.1 M | 1.07 M | 1.1 M | 1.1 M | 973 K | 1.1 M | 973 K | 985 K | 841 K | 985 K | 841 K | 880 K | 927 K | 880 K | 927 K | 1.12 M | 752 K | 1.12 M | 752 K | 538 K | 576 K | 538 K | 576 K | 514 K | 651 K | 514 K | 651 K | 470 K | 645 K | 470 K | 645 K | 497 K | 653 K | 497 K | 653 K |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Isoray (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Medical instruments industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
AtriCure
ATRC
|
$ 30.44 | 1.99 % | $ 1.45 B |  USA |
 |
Atrion Corporation
ATRI
|
- | - | $ 810 M | USA |
 |
AngioDynamics
ANGO
|
$ 10.67 | 0.66 % | $ 436 M | USA |
 |
Luminex Corporation
LMNX
|
- | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
- | -9.52 % | $ 20.6 M | USA |
 |
Alcon
ALC
|
$ 77.79 | 0.61 % | $ 40.4 B |  Schweiz |
 |
Antares Pharma, Inc.
ATRS
|
- | - | $ 955 M | USA |
 |
Cantel Medical Corp.
CMD
|
- | -1.18 % | $ 3.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
- | - | $ 282 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
- | -0.05 % | $ 10.3 B | USA |
 |
The Cooper Companies
COO
|
$ 71.04 | 1.6 % | $ 14.1 B | USA |
 |
Varian Medical Systems, Inc.
VAR
|
- | -0.02 % | $ 16.3 B | USA |
 |
Glaukos Corporation
GKOS
|
$ 98.94 | 1.98 % | $ 4.79 B | USA |
 |
Becton, Dickinson and Company
BDX
|
$ 160.27 | 0.57 % | $ 46.1 B | USA |
 |
Harvard Bioscience
HBIO
|
$ 5.01 | 5.81 % | $ 222 M | USA |
 |
Haemonetics Corporation
HAE
|
$ 59.7 | -0.37 % | $ 3 B | USA |
 |
electroCore
ECOR
|
$ 6.29 | 2.44 % | $ 34.7 K | USA |
 |
ICU Medical
ICUI
|
$ 126.96 | 0.88 % | $ 3.13 B | USA |
 |
InfuSystem Holdings
INFU
|
$ 9.57 | 2.79 % | $ 198 M | USA |
 |
iRhythm Technologies
IRTC
|
$ 113.77 | 0.68 % | $ 3.64 B | USA |
 |
Intuitive Surgical
ISRG
|
$ 483.46 | 2.39 % | $ 173 B | USA |
 |
Ekso Bionics Holdings
EKSO
|
$ 11.17 | -3.37 % | $ 27.1 M | USA |
 |
Repro Med Systems
KRMD
|
$ 4.29 | 0.23 % | $ 198 M | USA |
 |
Masimo Corporation
MASI
|
$ 175.4 | -0.05 % | $ 9.35 B | USA |
 |
Baxter International
BAX
|
$ 17.08 | -1.9 % | $ 8.76 B | USA |
 |
BioLife Solutions
BLFS
|
$ 19.08 | 3.92 % | $ 879 M | USA |
 |
Envista Holdings Corporation
NVST
|
$ 25.02 | 1.65 % | $ 4.2 B | USA |
 |
Nephros
NEPH
|
$ 2.92 | -16.57 % | $ 30.3 M | USA |
 |
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | USA |
 |
Merit Medical Systems
MMSI
|
$ 69.17 | -1.12 % | $ 4.09 B | USA |
 |
Predictive Oncology
POAI
|
- | - | $ 31.1 M | USA |
 |
OraSure Technologies
OSUR
|
$ 3.13 | 5.39 % | $ 230 M | USA |
 |
LeMaitre Vascular
LMAT
|
$ 110.75 | 2.49 % | $ 2.51 B | USA |
 |
Pro-Dex
PDEX
|
$ 49.63 | 2.41 % | $ 163 M | USA |
 |
Microbot Medical
MBOT
|
$ 2.73 | 1.49 % | $ 27.8 M |  Israel |
 |
ResMed
RMD
|
$ 230.61 | -0.1 % | $ 33.7 B | USA |
 |
Repligen Corporation
RGEN
|
$ 115.11 | 0.8 % | $ 6.41 M | USA |
 |
Retractable Technologies
RVP
|
$ 0.7 | -0.54 % | $ 21 M | USA |
 |
Teleflex Incorporated
TFX
|
$ 109.23 | 1.78 % | $ 4.87 B | USA |
 |
Pulse Biosciences
PLSE
|
$ 21.83 | 1.21 % | $ 1.47 B | USA |
 |
STAAR Surgical Company
STAA
|
$ 18.08 | -4.03 % | $ 896 M | USA |
 |
Stereotaxis
STXS
|
$ 1.91 | 1.06 % | $ 174 M | USA |
 |
STERIS plc
STE
|
$ 219.05 | 2.09 % | $ 21.6 B | USA |
 |
Utah Medical Products
UTMD
|
$ 64.0 | 1.14 % | $ 232 M | USA |
 |
West Pharmaceutical Services
WST
|
$ 240.31 | 2.06 % | $ 17.4 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
$ 11.73 | 1.65 % | $ 2.34 B | USA |
 |
Milestone Scientific
MLSS
|
$ 0.27 | -2.55 % | $ 21.5 M | USA |